Recombinant anti-interleukin-9 antibodies
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 13, 2008
Grant Date -
Nov 27, 2003
app pub date -
Apr 11, 2003
filing date -
Apr 12, 2002
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully